The Malaysia next generation sequencing market is projected to reach $145.28 million by 2036, at a CAGR of 11.8% from 2026 to 2036, up from an estimated $47.62 million in 2026. The market was valued at $42.60 million in 2025. The growth of this market is primarily fueled by the exceptionally high burden of inherited haemoglobin disorders, the demonstrated diagnostic superiority of sequencing in established screening applications, and the completion and expansion of the national genome programme. Additionally, the substitution of conventional testing methods in national screening applications, extension into agricultural and veterinary applications, and continued use of pathogen sequencing capabilities developed during the COVID-19 pandemic are expected to create substantial growth opportunities for market participants.
Approximately one in four Malaysians carries a haemoglobin abnormality, including alpha thalassaemia, beta thalassaemia, haemoglobin E, delta beta thalassaemia, and haemoglobin Constant Spring, creating substantial demand for genetic screening and molecular testing through the National Thalassaemia Screening Programme - a single screening centre at Hospital Raja Perempuan Zainab II alone analysed 13,721 blood samples collected from high school students participating in the national programme. The MyGenom project, Malaysia's first large-scale population genomics initiative, completed its first phase with more than 2,400 genomes sequenced, and its second phase is targeting a cumulative total of 10,000 genomes by 2028. According to the Malaysian National Cancer Registry, 168,822 cancer cases were recorded between 2017 and 2021, with more than 60% of cases diagnosed at stage three or four.
The key players operating in the Malaysia next generation sequencing market are Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), QIAGEN N.V. (Netherlands), Agilent Technologies, Inc. (U.S.), F. Hoffmann La Roche Ltd. (Switzerland), Revvity, Inc. (U.S.), Pacific Biosciences of California, Inc. (U.S.), Danaher Corporation (U.S.), Oxford Nanopore Technologies plc (U.K.), MGI Tech Co., Ltd. (China), BGI Genomics Co., Ltd. (China), Eurofins Scientific SE (Luxembourg), and Novogene Co., Ltd. (China). Illumina holds the leading position in this market, followed by Thermo Fisher Scientific, QIAGEN, Agilent Technologies, and Oxford Nanopore Technologies.
The Malaysia next generation sequencing market study presents historical market data value (2024, 2025), estimated current data (2026), and forecasts for 2036. This market is segmented by offering, application, and end user.
Among all the offerings, Commercial Sequencing and Outsourced Services are expected to account for the largest share of the market in 2026, reflecting the significant proportion of Malaysian demand served by commercial providers, including those located in Singapore and China, on behalf of institutions that do not operate their own sequencing infrastructure. Data Analysis and Bioinformatics is expected to register the fastest growth during the forecast period, at a CAGR of 13.4%, as the increasing volume of genomic information generated through clinical and research activities creates greater demand for processing and interpretation capabilities.
Among all the applications, Clinical Applications are expected to account for the largest share of the market in 2026, supported by growing use of sequencing in oncology, non-invasive prenatal testing, reproductive health, infectious diseases, and rare diseases. This segment is also expected to register strong growth during the forecast period, supported by increasing adoption of precision medicine and molecular diagnostics.
Among all the end users, Hospitals, Clinical and Reference Laboratories are expected to account for the largest share of the market in 2026 and are also expected to register the fastest growth among end users. Academic and Research Institutes represent another important source of demand, particularly through national genomics programmes and biomedical research activities.
Approximately one in four Malaysians carries a haemoglobin abnormality, including alpha thalassaemia, beta thalassaemia, haemoglobin E, delta beta thalassaemia, and haemoglobin Constant Spring, creating substantial demand for genetic screening and molecular testing through the National Thalassaemia Screening Programme - a single screening centre at Hospital Raja Perempuan Zainab II alone analysed 13,721 blood samples collected from high school students participating in the national programme. The MyGenom project, Malaysia's first large-scale population genomics initiative, completed its first phase with more than 2,400 genomes sequenced, and its second phase is targeting a cumulative total of 10,000 genomes by 2028. According to the Malaysian National Cancer Registry, 168,822 cancer cases were recorded between 2017 and 2021, with more than 60% of cases diagnosed at stage three or four.
The key players operating in the Malaysia next generation sequencing market are Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), QIAGEN N.V. (Netherlands), Agilent Technologies, Inc. (U.S.), F. Hoffmann La Roche Ltd. (Switzerland), Revvity, Inc. (U.S.), Pacific Biosciences of California, Inc. (U.S.), Danaher Corporation (U.S.), Oxford Nanopore Technologies plc (U.K.), MGI Tech Co., Ltd. (China), BGI Genomics Co., Ltd. (China), Eurofins Scientific SE (Luxembourg), and Novogene Co., Ltd. (China). Illumina holds the leading position in this market, followed by Thermo Fisher Scientific, QIAGEN, Agilent Technologies, and Oxford Nanopore Technologies.
The Malaysia next generation sequencing market study presents historical market data value (2024, 2025), estimated current data (2026), and forecasts for 2036. This market is segmented by offering, application, and end user.
Among all the offerings, Commercial Sequencing and Outsourced Services are expected to account for the largest share of the market in 2026, reflecting the significant proportion of Malaysian demand served by commercial providers, including those located in Singapore and China, on behalf of institutions that do not operate their own sequencing infrastructure. Data Analysis and Bioinformatics is expected to register the fastest growth during the forecast period, at a CAGR of 13.4%, as the increasing volume of genomic information generated through clinical and research activities creates greater demand for processing and interpretation capabilities.
Among all the applications, Clinical Applications are expected to account for the largest share of the market in 2026, supported by growing use of sequencing in oncology, non-invasive prenatal testing, reproductive health, infectious diseases, and rare diseases. This segment is also expected to register strong growth during the forecast period, supported by increasing adoption of precision medicine and molecular diagnostics.
Among all the end users, Hospitals, Clinical and Reference Laboratories are expected to account for the largest share of the market in 2026 and are also expected to register the fastest growth among end users. Academic and Research Institutes represent another important source of demand, particularly through national genomics programmes and biomedical research activities.
Key Questions Answered in the Report:
- What is the current revenue generated by the Malaysia next generation sequencing market?
- At what rate is the Malaysia next generation sequencing market demand projected to grow through 2036?
- What are the historical market sizes and growth rates of the Malaysia next generation sequencing market?
- What are the major factors driving the growth of this market? What are the major restraints affecting the market?
- Which segments in terms of offering, application, and end user are expected to create major traction for the manufacturers in this market?
- Who are the major players in the Malaysia next generation sequencing market? What are their specific product offerings in this market?
- What are the recent strategic developments in the Malaysia next generation sequencing market? What are the impacts of these strategic developments on the market?
Table of Contents
1. Market Definition & Scope
2. Research Methodology
3. Executive Summary
4. Market Insights
5. Malaysia NGS Market Assessment, By Offering
6. Malaysia NGS Market Assessment, By Application
7. Malaysia NGS Market Assessment, By End User
8. Competitive Landscape
9. 9. Company Profiles
10. Appendix
LIST OF TABLES
LIST OF FIGURES
Companies Mentioned
- Illumina, Inc.
- Thermo Fisher Scientific Inc.
- QIAGEN N.V.
- Agilent Technologies, Inc.
- F. Hoffmann La Roche Ltd.
- Revvity, Inc.
- Pacific Biosciences of California, Inc.
- Danaher Corporation
- Oxford Nanopore Technologies plc
- MGI Tech Co., Ltd.
- BGI Genomics Co., Ltd.
- Eurofins Scientific SE
- Novogene Co., Ltd. (China). Illumina holds the leading position in this market, followed by Thermo Fisher Scientific, QIAGEN, Agilent Technologies, and Oxford Nanopore Technologies
